ETF复盘资讯｜科技双雄飙升，港股通创新药ETF（520880）、港股互联网ETF（513770）涨超3%，513770登顶跨境ETF涨幅第一

Core Viewpoint - The Hong Kong stock market experienced an upward trend on July 15, driven by strong performances from technology and innovative pharmaceutical sectors, with significant gains in key stocks and ETFs [1][4]. Technology Sector - The Hong Kong Internet ETF (513770) saw a strong opening, with Bilibili-W leading with a rise of over 7% and Alibaba-W increasing by more than 6% in the afternoon [1]. - The Internet ETF closed with a gain of 3.46%, marking the highest increase among all cross-border ETFs in the market [1][7]. - The China Internet Index recorded a cumulative increase of over 28% since the beginning of the year, outperforming the Hang Seng Index and Hang Seng Tech Index [7][8]. Innovative Pharmaceutical Sector - The innovative pharmaceutical sector also showed significant movement, with CSPC Pharmaceutical leading with a rise of over 9% and Kangfang Bio reaching a historical high [2]. - The Hong Kong Innovative Pharmaceutical ETF (520880) saw an intraday price increase of nearly 4%, closing with a gain of 3.28% [2][5]. - The total amount of License-out transactions for innovative drugs in China reached nearly $66 billion in the first half of 2025, surpassing the total for the entire year of 2024, indicating a strong growth trend [4]. Market Outlook - Citic Securities noted that the current valuation of the Hong Kong stock market is at a low point, suggesting that insurance funds may expand their investment scope, potentially leading to a rebound in southbound capital [4]. - Galaxy Securities expects the Hong Kong market to trend upward with a focus on structural opportunities, particularly in the technology sector, which benefits from strong policy support and favorable earnings growth [4]. - The innovative pharmaceutical sector is anticipated to benefit from recent policy changes regarding drug insurance coverage, enhancing the accessibility of high-priced innovative drugs [4].